利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.027 秒)

    Purine derivatives as adenosine A1 receptor agonists and methods of use thereof
    5.
    发明申请
    Purine derivatives as adenosine A1 receptor agonists and methods of use thereof 有权
    嘌呤衍生物作为腺苷A1受体激动剂及其使用方法

    公开(公告)号：US20050282768A1

    公开(公告)日：2005-12-22

    申请号：US11137632

    申请日：2005-05-25

    申请人： Prakash Jagtap ,  Csaba Szabo ,  Andrew Salzman

    发明人： Prakash Jagtap ,  Csaba Szabo ,  Andrew Salzman

    IPC分类号： A61K31/7076 ,  C07D473/34 ,  C07H19/12

    CPC分类号： C07H19/167 ,  C07D473/34 ,  C07H19/12

    摘要： The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's rate of metabolism, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof.

    摘要翻译： 本发明涉及嘌呤衍生物; 包含有效量的嘌呤衍生物的组合物; 以及降低动物代谢率的方法，保护动物的心脏免受心脏停搏期间的心肌损伤; 或用于治疗或预防心血管疾病，神经障碍，缺血状况，再灌注损伤，肥胖症，消耗性疾病或糖尿病，包括向有需要的动物施用有效量的嘌呤衍生物。

    Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
    7.
    发明授权
    Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives 失效
    使用取代的菲啶酮衍生物治疗神经变性疾病的方法

    公开(公告)号：US06531464B1

    公开(公告)日：2003-03-11

    申请号：US09606587

    申请日：2000-06-29

    申请人： Csaba Szabo ,  Prakash Jagtap ,  Garry Southan ,  Andrew Salzman

    发明人： Csaba Szabo ,  Prakash Jagtap ,  Garry Southan ,  Andrew Salzman

    IPC分类号： A61K3133

    CPC分类号： C07D279/02 ,  C07D221/12

    摘要： This invention provides a novel class of substituted 6(5H)phenanthridinone compounds. The invention also includes pharmaceutical compositions, and methods of making and using the compounds, or a pharmaceutically acceptable salt, hydrate, prodrug, or mixture thereof. Methods of using the compounds and pharmaceutical compositions for treating neurodegenerative disorders, such as multiple sclerosis are also described.

    摘要翻译： 本发明提供了一类新的取代的6（5H）菲啶酮化合物。 本发明还包括药物组合物，以及制备和使用化合物或其药学上可接受的盐，水合物，前药或其混合物的方法。 还描述了使用化合物和药物组合物治疗神经变性疾病如多发性硬化的方法。

    Purine derivatives and methods of use thereof
    9.
    发明申请
    Purine derivatives and methods of use thereof 有权
    嘌呤衍生物及其使用方法

    公开(公告)号：US20060128652A1

    公开(公告)日：2006-06-15

    申请号：US11230089

    申请日：2005-09-19

    申请人： Prakash Jagtap ,  Andrew Salzman ,  Csaba Szabo

    发明人： Prakash Jagtap ,  Andrew Salzman ,  Csaba Szabo

    IPC分类号： A61K31/7076 ,  C07H19/16

    CPC分类号： C07H19/167 ,  C07H19/16

    摘要： The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for treating or preventing an ischemic condition, reperfusion injury, a cellular proliferative disorder, a cardiovascular disease, a neurological disorder, a skin disorder, a radiation-induced injury, a wound, or an inflammatory disease comprising administering an effective amount of a Purine Derivative to a subject in need thereof.

    摘要翻译： 本发明涉及嘌呤衍生物 包含有效量的嘌呤衍生物的组合物; 以及用于治疗或预防缺血状况，再灌注损伤，细胞增殖性疾病，心血管疾病，神经障碍，皮肤病症，辐射诱发的损伤，伤口或炎性疾病的方法，包括施用有效量的 嘌呤衍生物对有需要的受试者。

    Nucleoside compounds and compositions thereof
    10.
    发明授权
    Nucleoside compounds and compositions thereof 失效

    公开(公告)号：US06903079B2

    公开(公告)日：2005-06-07

    申请号：US10320780

    申请日：2002-12-16

    申请人： Prakash Jagtap ,  Garry Southan ,  Andrew Salzman ,  Csaba Szabo ,  Siya Ram

    发明人： Prakash Jagtap ,  Garry Southan ,  Andrew Salzman ,  Csaba Szabo ,  Siya Ram

    IPC分类号： A61P19/02 ,  C07D209/46 ,  C07D401/12 ,  C07D403/12 ,  C07D473/34 ,  C07D473/40 ,  C07H19/04 ,  C07H19/167 ,  A61K31/7076

    CPC分类号： C07D401/12 ,  C07D209/46 ,  C07D403/12 ,  C07D473/34 ,  C07D473/40 ,  C07H19/04

    摘要： The invention provides a novel class of substituted nucleoside derivatives having the formula: A-Z1-L-Z2-G wherein: A and G are connected via Z1 and Z2 respectively, to a linker, L; and A is: wherein: X1 and X2 are N; X3 is —N═CH; R1 and R2 are independently H, alkyl, NH2, OH, SH, Cl, NHR9, or N═NR9, where R9 is alkyl, aryl, or arylalkyl; R5 and R6 are independently alkyl, or R5 and R6 taken together form a —C(CH3)2— group; Z1 is —CH2O—, —CH2NR10—, —CH2NR10C(O)—, —CONR10—, —CO2—, —CH2NHCONH—, —CH2—, —CH2NHCSNH—, —CO—, —CH2CO2—, —NHCO2—, —S—, —SO2—, —CH2S—, or —SO—; Z2 is —NR10CO—, —C(O)NR10—, —NHCONH—, —OC(O)—, —C(O)O—, NHCS, —CSNH—, —NHCSNH—, —O—, —CO—, —OCO—, —OCONH—, —NH—, —CH2—, —CH—alkyl—, —NHCO2—, —S—, —SO2—, CS—, or —SO—; L is H, O, S, C1-15 alkylene chain optionally substituted in one or more positions, a 5, 6 or 7 membered carbocycle, piperidine, piperazine, pyrole, imidazole, benzimidazole, tetrazoles, indole, isoquinoline, quinoline, or pyrrolidine, any of the 5, 6 or 7 membered carbocycle, piperidine, piperazine, pyrole, imidazole, benzimidazole, tetrazoles, indole, isoquinoline, quinoline, or pyrrolidine groups being unsubstituted or substituted with one or more lower alkyl, hydroxyl, keto, amino, aminoalkyl, halo, or alkoxy groups, provided that L is not H when Z1 is O, and when L=H, Z2 and G are absent; and G is H, OH, SH, NH2, CO2H, unsubstituted or substituted alkyl, aryl, alkylaryl, carbocyclic, biphenyl, piperidine, piperazine, pyrole, imidazole, benzimidazole, tetrazole, indole, isoquinoline, quinoline, isoindolinyl, tetrahydroindolinonyl, phthalimidyl, or pyrrolidine. Pharmaceutical compositions, and methods of making and using the compounds, or pharmaceutically acceptable salts, hydrates, or mixtures thereof are also described.